That stealthy single-cell sequencing startup from Flagship Pioneering now has a proper name: Cellarity.

The company, which will likely use artificial intelligence and machine-learning models to analyze data sets from single-celled sequencing and other sources, now employs about 23 employees, roughly double the number it had in December. The company will be working on drugs for cancer as well as diseases that affect the immune system and the body’s inflammatory response, according to the company’s December presentation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy